Cephalon Says Back Pain Drug Successful
Posted on: Thursday, 12 October 2006, 12:00 CDT
Results from a phase III clinical trial of Fentora, manufactured by Cephalon, has demonstrated the efficacy of the drug in the management of low back pain for those who patients who are able to tolerate opioids.
In the study a significant improvement in pain intensity was observed within 10 minutes and at all subsequent time points measured throughout the assessment period. Adverse events were typical for opioids.
"The results of this study suggest that Fentora may have application beyond its current indication in cancer and provide important support to our strategy for future label expansion in breakthrough pain associated with multiple chronic pain conditions," said Dr Lesley Russell, senior vice president, Worldwide Medical and Regulatory Operations at Cephalon.
An estimated 51% of people with chronic pain report back pain, making it the most common chronic pain condition, according to the American Chronic Pain Association.
Fentora has been approved by the FDA for patients with cancer pain who can also tolerate opioids.
Source: Datamonitor
Related Articles
- Innocoll Files Investigational New Drug Application for Its CollaRx(R) BUPIVACAINE TOPICAL for the Treatment of Painful Chronic Skin Ulcers and Burns
- Cephalon Warns Physicians on Fentora Prescription
- Akela Completes Patient Enrollment for Mid-Stage Trial
- Cephalon Drug Works for Breakthrough Pain
- Cephalon Reports Positive Results for Pain Drug Fentora
- Wyeth and Progenics Initiate Phase II Opioid Study
- Human Genome Lupus Test Fails to See Goals
- Human Genome Lupus Test Misses Goals
- Using Celebrex a Patient's Decision
- Parasympathetic Nervous System at Risk
 |
 |
User Comments (0)
RSS Feeds